Virica Biotech news
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, Science and Economic Development Canada (ISED) through the Innovative Solutions Canada (ISC) program. This funding supports Virica’s collaboration with the National Research Council of Canada’s (NRC) Cell and Gene Therapy Challenge program to enhance the manufacturing of an affordable version of AAV-LPL, a gene thera
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers
Virica is excited to be a part of Advanced Therapies Week, Jan 25th-Jan28th, 2022 at the Miami Convention Center. We are a proud to be a Dynamk Capital portfolio company. Visit us in the Technology of Tomorrow Zone, Booth 11.
We look forward to meeting you at Advance Therapies Week!
We now have officially launched our Process Innovation Facility! Take a look at where we enhance the manufacturing of viral medicine.
Virica Biotech Inc., a leading life science developer of solutions for scaling of viral medicines, announced today the first closing of its Series A financing. The round, led by Dynamk Capital, is expected to close with additional investors by the end of Q4-2021. The investment strengthens Virica’s already impressive growth trajectory, as it gears up to become a premier manufacturing partner for global viral medicine prod
Virica’s Founder and CEO Dr. Jean-Simon Diallo discusses his latest virology research at the Ottawa Hospital Research Institute, which focuses on Covid-19 and is funded by the Ontario Government, with CTV Ottawa Morning. His team is using a biosensor that detects the interaction with the virus and its receptor which will allow them to rapidly test small molecules and drugs for their ability to block the virus which is crucial not only for
As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved ones are facing today, creating, manufacturing, testing, and delivering novel vaccines for a global population of more than 7 billion is truly a daunting challenge. As res